$3.50 Million in Sales Expected for Crispr Therapeutics AG (CRSP) This Quarter

Share on StockTwits

Analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post $3.50 million in sales for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $9.50 million and the lowest estimate coming in at $500,000.00. Crispr Therapeutics reported sales of $2.39 million during the same quarter last year, which would suggest a positive year over year growth rate of 46.4%. The business is scheduled to issue its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $9.10 million for the current year, with estimates ranging from $3.40 million to $23.20 million. For the next year, analysts anticipate that the business will report sales of $34.78 million, with estimates ranging from $8.00 million to $91.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, August 8th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.19). The firm had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $1.47 million. Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%.

A number of research analysts have recently commented on CRSP shares. Chardan Capital restated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research note on Wednesday, August 8th. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Monday, September 17th. Zacks Investment Research upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 12th. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, Guggenheim started coverage on Crispr Therapeutics in a research note on Tuesday, October 9th. They issued a “neutral” rating for the company. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $62.47.

Shares of CRSP traded down $1.16 on Tuesday, reaching $36.04. The stock had a trading volume of 615,156 shares, compared to its average volume of 1,408,876. The stock has a market cap of $1.70 billion, a PE ratio of -21.08 and a beta of 3.67. Crispr Therapeutics has a 12-month low of $16.51 and a 12-month high of $73.90.

A number of large investors have recently made changes to their positions in the business. Federated Investors Inc. PA purchased a new position in Crispr Therapeutics during the second quarter valued at $37,101,000. BlackRock Inc. raised its stake in Crispr Therapeutics by 3.7% during the second quarter. BlackRock Inc. now owns 593,527 shares of the company’s stock valued at $34,876,000 after buying an additional 21,309 shares during the last quarter. Orbimed Advisors LLC raised its stake in Crispr Therapeutics by 375.3% during the second quarter. Orbimed Advisors LLC now owns 496,200 shares of the company’s stock valued at $29,157,000 after buying an additional 391,799 shares during the last quarter. ARK Investment Management LLC raised its stake in Crispr Therapeutics by 544.0% during the second quarter. ARK Investment Management LLC now owns 467,140 shares of the company’s stock valued at $27,449,000 after buying an additional 394,606 shares during the last quarter. Finally, Casdin Capital LLC raised its stake in Crispr Therapeutics by 63.0% during the second quarter. Casdin Capital LLC now owns 220,000 shares of the company’s stock valued at $12,927,000 after buying an additional 85,000 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Featured Article: Ex-Dividend

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Coupa Software Inc  is Battery Partners VIII LLC’s Largest Position
Coupa Software Inc is Battery Partners VIII LLC’s Largest Position
Atlas Capital Advisors LLC Sells 1,197 Shares of iShares Core MSCI Pacific ETF
Atlas Capital Advisors LLC Sells 1,197 Shares of iShares Core MSCI Pacific ETF
BerganKDV Wealth Management LLC Has $245,000 Position in CGI
BerganKDV Wealth Management LLC Has $245,000 Position in CGI
Celgene Co.  Position Raised by B & T Capital Management DBA Alpha Capital Management
Celgene Co. Position Raised by B & T Capital Management DBA Alpha Capital Management
Atlas Capital Advisors LLC Sells 11,865 Shares of iShares Edge MSCI Intl Momentum Factor ETF
Atlas Capital Advisors LLC Sells 11,865 Shares of iShares Edge MSCI Intl Momentum Factor ETF
Atlas Capital Advisors LLC Cuts Stake in Invesco FTSE RAFI Developed Markets ex-U.S. ETF
Atlas Capital Advisors LLC Cuts Stake in Invesco FTSE RAFI Developed Markets ex-U.S. ETF


Leave a Reply

 
© 2006-2018 Zolmax.